Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Neoplasms 7Prostatic Neoplasms 5Brain Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Radiation Injuries 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemangioma 2Breast Neoplasms 2Urogenital Neoplasms 1Scleroderma, Localized 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Popliteal Cyst 1Polycystic Ovary Syndrome 1Pneumonia, Viral 1Pneumonia 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Optic Neuritis 1Neurodermatitis 1Neoplastic Cells, Circulating 1Neoplasms, Fibrous Tissue 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 108Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Adrenal Cortex Hormones × Clear all
NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01414205 2017-04-17

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Genentech, Inc.

Phase 2 Completed
80 enrolled 18 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡